MOSCOW, March 2 – RIA Novosti. Italian pharmaceutical companies are showing great interest in the joint production of the Russian vaccine against the Sputnik V coronavirus with Russia, Vincenzo Trani, President of the Italian-Russian Chamber of Commerce (IRTP), told RIA Novosti.
Earlier, the chief physician of the Italian National Institute of Infectious Diseases named after Lazzaro Spallanzani Francesco Vaya said that Italy would send two inspectors to Russia to check the manufacturing enterprises of the Sputnik V coronavirus vaccine.
“Since September 2020, as President of the Italian-Russian Chamber of Commerce, I have received more and more questions about the Sputnik V vaccine and its possible production and commercialization in Italy … The vaccine can be an opportunity to join forces and work together to protect public health, this will allow Italy to become a partner in vaccine production and guarantee the population more choice in vaccination, as other countries have done, “Trani said.
He noted that the Gamalea Institute, which developed Sputnik V, enjoys great prestige in Italian scientific circles: he collaborated, among other things, with the Spallanzani Institute of Infectious Diseases in Rome in various research projects.
“I must note that (Italian pharmaceuticals – ed.) Companies have become active quickly, albeit timidly, since Europe still does not have the necessary permits for the sale of Russian vaccines. There is great interest in the joint production of vaccines, but, unfortunately, we have witnessed We have repeatedly invited Italian institutions to come and check the Russian vaccine, in many cases we did not receive an answer, and in others, real skepticism towards Russia ruled out any possible dialogue, “said the head of the Italian-Russian Chamber of Commerce.
The interlocutor of the agency stressed that Italy and Europe are in great need of vaccines, and Russia can supply quality drugs, which is confirmed by the latest international studies.
The Sputnik V vaccine was registered by the Ministry of Health of the Russian Federation in August 2020, it was developed by the Gamaleya Research Center for Electrochemistry. The scientific journal Lancet has published the results of the third phase of clinical research “Sputnik V”, confirming its high efficiency and safety. During phase III clinical trials, Sputnik V demonstrated high rates of efficacy, immunogenicity and safety – the vaccine efficacy was 91.6%. As the director of the Gamaleya Center Alexander Gintsburg noted, the Russian vaccine provides one hundred percent protection against severe and moderate cases of coronavirus infection.
Currently “Sputnik V” is registered in 39 countries – Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, the United Arab Emirates, Iran, the Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, the Republic of Serbian (Entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova and Slovakia.